Literature DB >> 12011381

Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations.

E F Morand1, M Leech, H Weedon, C Metz, R Bucala, M D Smith.   

Abstract

OBJECTIVE: Cytokines play an important role in the pathology of rheumatoid arthritis (RA). Macrophage migration inhibitory factor (MIF) is a cytokine with a broad spectrum of actions, including induction of monocyte tumour necrosis factor alpha (TNF-alpha). Evidence of the expression and proinflammatory activity of MIF has recently been demonstrated in RA synovium and in animal models of RA. We wished to assess the relationship between MIF expression in synovium and clinical disease.
METHODS: Computer-assisted analysis of the cytokine content of arthroscopically obtained biopsies of RA synovium, using paired samples from eight patients with active and inactive/treated disease, was compared with documented clinical parameters.
RESULTS: Synovial MIF immunostaining correlated strongly with disease activity as measured by CRP concentration. Reductions in clinical disease parameters, including CRP, tender and swollen joint counts, were accompanied by significant reductions in synovial MIF. Synovial TNF-alpha, transforming growth factor beta (TGF-beta) and interleukin (IL) 10 also showed a significant reduction in association with reduced disease activity, while IL-1 beta and IL-1 receptor agonist did not.
CONCLUSION: The correlation of synovial MIF with disease activity corroborates existing evidence of the role of this cytokine in RA. The demonstration that only MIF and TNF-alpha show significant variation in synovial cytokine content with clinical remission suggests that MIF is an important member of the cytokine hierarchy in RA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011381     DOI: 10.1093/rheumatology/41.5.558

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  41 in total

1.  Macrophage migration inhibitory factor deficiency augments cardiac dysfunction in Type 1 diabetic murine cardiomyocytes.

Authors:  Chao Tong; Alex Morrison; Xiaoyan Yan; Peng Zhao; Eddie D Yeung; Jingying Wang; Jianxin Xie; Ji Li
Journal:  J Diabetes       Date:  2010-12       Impact factor: 4.006

Review 2.  Macrophage migration inhibitory factor (MIF): a promising biomarker.

Authors:  Gerrit Grieb; Melanie Merk; Jürgen Bernhagen; Richard Bucala
Journal:  Drug News Perspect       Date:  2010-05

3.  Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis.

Authors:  Ran Gu; Leilani L Santos; Devi Ngo; HuaPeng Fan; Preetinder P Singh; Gunter Fingerle-Rowson; Richard Bucala; Jiake Xu; Julian M W Quinn; Eric F Morand
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

4.  Direct modification of the proinflammatory cytokine macrophage migration inhibitory factor by dietary isothiocyanates.

Authors:  Kristin K Brown; Frances H Blaikie; Robin A J Smith; Joel D A Tyndall; Hongqi Lue; Jürgen Bernhagen; Christine C Winterbourn; Mark B Hampton
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

5.  Independent roles of macrophage migration inhibitory factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking.

Authors:  Julia L Gregory; Pam Hall; Michelle Leech; Eric F Morand; Michael J Hickey
Journal:  Microcirculation       Date:  2009-11       Impact factor: 2.628

6.  Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation.

Authors:  L L Santos; A Dacumos; J Yamana; L Sharma; E F Morand
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

7.  Increased TLR4 expression and downstream cytokine production in immunosuppressed adults compared to non-immunosuppressed adults.

Authors:  Dana W Dunne; Albert Shaw; Linda K Bockenstedt; Heather G Allore; Shu Chen; Stephen E Malawista; Lin Leng; Yuka Mizue; Marta Piecychna; Lin Zhang; Virginia Towle; Richard Bucala; Ruth R Montgomery; Erol Fikrig
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

8.  Induction of macrophage migration inhibitory factor in ConA-stimulated rheumatoid arthritis synovial fibroblasts through the P38 map kinase-dependent signaling pathway.

Authors:  Hae-Rim Kim; Mi-Kyung Park; Mi-La Cho; Kyoung-Woon Kim; Hye-Joa Oh; Jin-Sil Park; Yang-Mi Heo; Sang-Heon Lee; Ho-Youn Kim; Sung-Hwan Park
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 3.165

9.  The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study.

Authors:  Yvonne C Lee; Lori B Chibnik; Bing Lu; Ajay D Wasan; Robert R Edwards; Anne H Fossel; Simon M Helfgott; Daniel H Solomon; Daniel J Clauw; Elizabeth W Karlson
Journal:  Arthritis Res Ther       Date:  2009-10-29       Impact factor: 5.156

10.  Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.

Authors:  C A Wijbrandts; S I van Leuven; H D Boom; D M Gerlag; E G S Stroes; J J P Kastelein; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-08-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.